Results 201 to 210 of about 326,497 (313)

COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape. [PDF]

Life (Basel)
Huang TS, Chao JY, Chang HH, Lin WR, Lin WH.   +4 more
europepmc   +1 more source

[Anti-arrhythmia agents and sudden death].

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 1992
openaire   +1 more source

Translationally controlled tumor protein interacts with connexin 43 and facilitates intercellular coupling between cardiomyocytes. [PDF]

Front Cell Dev Biol
Hu Y, Cai W, Hidaka Y, Hiraishi K, Cang J, Umemura M, Yokoyama U, Knollmann BC, Ishikawa Y, Fujita T.   +9 more
europepmc   +1 more source

[Classification of anti-arrhythmia agents and their characteristics].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1991
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Advances in applications of anti-arrhythmia agents and safety evaluation

Pharmaceutical Care and Research, 2012
Tao Chen, Tao Xu, DeNing Liao, XiaoHua Zhuang   +3 more
openaire   +3 more sources

[Cardiotropic effect of anti-arrhythmia agents].

Farmakologiia i toksikologiia, 1979
In experiments on contractile proteins isolated from the myocardium rather than from the musculus gastrocnemius it was shown that in contradistinction to lidocain the drugs quinine, quinidine, novocainamide, papaverin, obsidan and isoptin at a concentration of 3 .
Shevchenko Ai
openaire   +2 more sources

[Clinical pharmacology of anti-arrhythmia agents].

Revista de medicina de la Universidad de Navarra, 1984
J R, Azanza Perea, J M, Honorato Pérez, R, Cuena Boy   +2 more
openaire   +2 more sources

[Drug information: agents for the treatment of arrhythmias. Therapeutic main group: anti-arrhythmia agents. 16. (3). Anti-arrhythmia agents with action on ventricular arrhythmias].

Sygeplejersken, 1981
Lumholtz Ib
openaire   +2 more sources

[New anti-arrhythmia agents].

Zeitschrift fur Kardiologie, 1993
Use of class-I antiarrhythmic agents (encainide, flecainide or moricizine) to suppress asymptomatic ventricular premature depolarizations does not decrease, but rather increases mortality from cardiac events after myocardial infarction. These patients should not be treated with antiarrhythmic drugs until improved survival is shown in a controlled ...
P, Honerjäger, G, Schmidt
openaire   +1 more source

[The anti-arrhythmia action of combinations of N-propylajmaline bromide with anti-arrhythmia agents of different classes].

Farmakologiia i toksikologiia, 1990
In experiments on 68 dogs with ventricular arrhythmia at the late stage of experimental myocardial infarction caused by the coronary artery branch occlusion it was shown that combinations of N-propylaimaline bromide (IA class of antiarrhythmic agents) with trimecaine (IB class) or anapriline (II class) or phynoptine (IV class) induce a significant ...
E I, Gendenshteĭn, V P, Balashov, Ia V, Kostin, V E, Oleĭnikov   +3 more
openaire   +1 more source